HBM Holdings (SEHK:2142) Valuation After Solstice Oncology Partnership On HBM4003 Rights Outside Greater China

Simply Wall St.02-24

HBM Holdings (SEHK:2142) shares have been in focus after the company signed an exclusive license and equity partnership with Solstice Oncology, centered on its clinical asset HBM4003 outside Greater ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613046793?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-02-24 15:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613046793","market":"nz","top_or_hot":-1,"title":"HBM Holdings (SEHK:2142) Valuation After Solstice Oncology Partnership On HBM4003 Rights Outside Greater China","media":"Simply Wall St.","content":"<div>\n<p>HBM Holdings (SEHK:2142) shares have been in focus after the company signed an exclusive license and equity partnership with Solstice Oncology, centered on its clinical asset HBM4003 outside Greater ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-valuation-after-solstice-oncology-part\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM Holdings (SEHK:2142) Valuation After Solstice Oncology Partnership On HBM4003 Rights Outside Greater China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM Holdings (SEHK:2142) Valuation After Solstice Oncology Partnership On HBM4003 Rights Outside Greater China\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-24 15:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-valuation-after-solstice-oncology-part><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HBM Holdings (SEHK:2142) shares have been in focus after the company signed an exclusive license and equity partnership with Solstice Oncology, centered on its clinical asset HBM4003 outside Greater ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-valuation-after-solstice-oncology-part\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HBM","symbol_name":"HudBay Minerals Inc","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-valuation-after-solstice-oncology-part","article_id":"2613046793","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-valuation-after-solstice-oncology-part","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2613046793","pubTimestamp":1771918325,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"HBM Holdings (SEHK:2142) shares have been in focus after the company signed an exclusive license and equity partnership with Solstice Oncology, centered on its clinical asset HBM4003 outside Greater China.\nSee our latest analysis for HBM Holdings.\nThe Solstice agreement arrives as momentum in HBM Holdings' shares has picked up again, with a 1 day share price return of 4.41% and 7 day share price return of 8.12%, while the 1 year total shareholder return of 123.82% and 3 year total shareholder...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"HBM":"HudBay Minerals Inc","BK1583":"高瓴概念","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","02142":"和铂医药-B","BK1161":"生物科技","BK4168":"多种金属与采矿","BK1574":"生物医药B类股"},"translate_title":"HBM Holdings(SEHK：2142)与Solstice Oncology合作获得HBM4003大中华区以外权利后的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":0.9,"DCF":1,"HBM":0.9},"content_text":"HBM Holdings (SEHK:2142) shares have been in focus after the company signed an exclusive license and equity partnership with Solstice Oncology, centered on its clinical asset HBM4003 outside Greater China. See our latest analysis for HBM Holdings. The Solstice agreement arrives as momentum in HBM Holdings' shares has picked up again, with a 1 day share price return of 4.41% and 7 day share price return of 8.12%, while the 1 year total shareholder return of 123.82% and 3 year total shareholder return of more than 4x point to a stock where optimism has already played a meaningful role in long term performance. If this kind of biotech deal making has caught your attention, it could be a good moment to see which other healthcare names are gaining traction through our 111 healthcare AI stocks. With the stock up sharply over 1 year yet trading at a discount of around 41% to the HK$18.01 analyst price target, the key question is whether HBM is still mispriced or if the market is already factoring in future growth. AdvertisementPrice-to-Earnings of 18.7x: Is it justified? On a P/E of 18.7x, HBM Holdings trades well below several benchmark averages. This suggests the current HK$12.78 price is not stretched relative to peers. The P/E ratio compares the current share price to earnings per share. For a biopharma name like HBM, it effectively shows how much investors are paying for each dollar of reported profit. HBM screens as good value against its direct biotech peer group, with its 18.7x P/E below the peer average of 84.5x and also under the wider Asian biotech average of 41.8x. At the same time, our fair P/E estimate of 15.1x implies the current multiple sits above the level our model suggests the market could gravitate toward if expectations cool. Explore the SWS fair ratio for HBM Holdings Result: Price-to-Earnings of 18.7x (ABOUT RIGHT) However, you still have to weigh execution risks around HBM4003’s clinical progress and the impact of a 12.2% net income decline on how long investors stay patient. Find out about the key risks to this HBM Holdings narrative. Another View: Our DCF Model Indicates HK$12.78 May Be Expensive While the 18.7x P/E looks reasonable next to peers, our DCF model suggests a different picture. On that basis, HBM Holdings at HK$12.78 sits above an estimated future cash flow value of about HK$9.46, which points to a higher valuation relative to this estimate rather than a wide margin of safety. Look into how the SWS DCF model arrives at its fair value. 2142 Discounted Cash Flow as at Feb 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out HBM Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 231 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps If this mix of optimism and caution has you on the fence, it is worth taking a closer look for yourself and deciding quickly where you stand. You can start with the 2 key rewards and 3 important warning signs that our work has surfaced. Looking for more investment ideas? If HBM has sharpened your focus, this is the moment to broaden your watchlist and hunt for other stocks that might suit your approach.  Zero in on quality at a discount by scanning our 231 high quality undervalued stocks and see which names currently stand out on price and fundamentals. Prioritize resilience and sleep easier at night by checking companies in the 325 resilient stocks with low risk scores that score well on overall risk metrics. Hunt for future leaders before the crowd catches on using the screener containing 568 high quality undiscovered gems and spot underfollowed businesses with solid profiles.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if HBM Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613046793","isCrawlerRequest":true}